Congenital bilateral absence of the vas deferens (CBAVD) is a recognised cause of male infertility most frequently linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ...
The FDA has expanded indications for two targeted combination treatments, Alyftrek and Trikafta, that will now benefit more ...
Vertex Pharmaceuticals (VRTX) announced on Wednesday that the U.S. FDA approved label expansions for Alyftrek and Trikafta, its treatments for cystic fibrosis, a hereditary disease caused by mutations ...
This photo provided by Emilys Entourage in April 2025 shows Emily Kramer-Golinkoff, who has cystic fibrosis caused by a rare genetic mutation, during a trip to Maine. (Emilys Entourage via AP) ...
- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...
Add Yahoo as a preferred source to see more of our stories on Google. This photo provided by Emily’s Entourage in April 2025 shows Emily Kramer-Golinkoff, who has cystic fibrosis caused by a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results